Nichi-Iko Pharmaceutical has acquired Sagent Pharmaceuticals in a deal worth approximately $736 million. The acquisition brings together two leading companies in the generics market, creating stronger growth opportunities for each business. The transaction enhances Nichi-Iko’s platform in the U.S. market to commercialize its biosimilar product pipeline and increase its presence in injectables. Through the acquisition, Nichi-Iko will raise its profile in the domestic and international generics...